Matteo Lambertini, MD PhD· @matteolambe · X·· 2 days agoScore90
Body
Oral abstract #BreastCancer session at #ESMO26: updated data from the TALENT trial showing activity of neoadjuvant #TrastuzumabDeruxtecan in HER2-low HR+ disease
@OncoAlert @myESMO
542 views · 20 likes · 10 reposts · 0 replies
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgSource: Matteo Lambertini, MD PhD · x.com